Covid-19 dermatoses: Acral vesicular pattern evolving into bullous pemphigoid

P.K.C. Goon1 | O. Bello1 | L.A. Adamczyk2 | J.Y.H. Chan3 | H. Sudhoff4 | C.C. Banfield1

1Department of Dermatology, Peterborough City Hospital, North West Anglia Foundation Trust (NWAAF), Peterborough, UK
2Department of Histopathology, Peterborough City Hospital, North West Anglia Foundation Trust (NWAAF), Peterborough, UK
3Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4University Hospital of Bielefeld, Bielefeld, Germany

Correspondence
Peter K. C. Goon, Department of Dermatology, Peterborough City Hospital, Edith Cavell Campus, North West Anglia NHS Foundation Trust, Bretton Gate, Peterborough PE3 9GZ, UK. Email: peter.goon@nhs.net

Abstract
Bullous pemphigoid (BP) appears to be rising in incidence across the Western World, especially in the elderly. Some of the pathogenetic mechanisms involving antigen mimicry and antibody cross-reactivity have been elucidated for cases associated with neurological disease and certain drugs. There have been reports of cutaneous manifestations of Covid-19 (SARS-Cov2 infection) as the pandemic has raged across the world. We report here a case of prolonged Covid-19, symptomatic with dermatoses only, which was seen to evolve initially from a maculo-papular exanthema with acral vesicular dermatitis, into classical BP disease. This was confirmed histologically by positive skin autoantibody serology, direct IMF on perilesional skin and also salt-split IMF. Although possible that the development of BP could be a purely co-incidental finding during Covid-19, we suggest that it is more likely that prolonged SARS-Cov2 infection triggered an autoimmune response to the basement membrane antigens, BP 180 and 230. To our knowledge, this is the first case of BP developing during concurrent Covid-19 disease. It will be necessary to continue dermatological surveillance as the pandemic continues, to collate data on BP incidence and to test these patients for Covid-19 disease. As the pandemic continues, even potential and rare associations such as this will be clarified eventually.

1 CASE REPORT

Bullous pemphigoid (BP) is a rare disease (<5/100,000)1 but reported to be increasing in incidence, particularly in the over 70s.2–4 The various risk factors associated with this rise are the increasingly elderly populations in Western Europe, an increasing use of drugs such as dipeptidyl-peptidase IV inhibitors (DPP4i) in the treatment of type 2 diabetes mellitus,5,6 psychotropic drugs (particularly phenothiazines with aliphatic side chains),7 checkpoint inhibitors such as anti-PD-1, and PD-L18 and neurological disease burden such as dementia, stroke, multiple sclerosis, and so on9,10 amongst the elderly. Cross reactivity between the neuronal and epithelial isoforms of BP2309,10, inhibition of plasm by DPP4i altering cleavage of BP180 within the NC-16A domain11 and other not yet elucidated mechanisms are thought to be responsible for the rising incidence of BP.

The American Academy of Dermatology and the British Association of Dermatologists have categorised several of the most common, mainly referenced by studies from Spain12 and Italy.13,14 None report an association with autoimmune bullous disease. Here we present a case of BP arising during prolonged Covid-19 disease for 6 weeks.

An 82-year-old female was admitted to hospital at the end of April after an episode of angina pectoris. Echocardiography revealed critical aortic stenosis with prognosis expected to be less than 1 year if untreated. Her past medical history included ischaemic heart...


**What’s already known about this topic?**

- Covid-19 disease has been associated with a spectrum of dermatoses
- Common presentations in up to 20% of patients include exanthema, pseudo-chilblain like acral lesions ‘Covid toes’, livedo-/retiform purpuric/necrotic vascular lesions, acute urticarial lesions, and vesicular/varicella-like lesions
- A multi-system inflammatory syndrome in children akin to Kawasaki syndrome has been described

**What does this study add?**

- To our knowledge, this is the first description of classic Bullous Pemphigoid evolving from vesicular lesions caused by prolonged SARS-CoV2 induced skin inflammation

---

**2 | DISCUSSION**

We hypothesise that prolonged inflammation of the skin during the initial phase of the viral exanthem has left the damaged basement membrane open and susceptible to immune recognition by the host’s immune system, and the subsequent development of autoimmune bodies to BP antigens 180 or 230, possibly through antigenic mimicry of viral antigens in an analogous manner to ‘Fogo Selvagem’. This is an endemic autoimmune bullous disease seen in clusters along rivers and waterways in Brazil and South America. It has been hypothesized that bites by *Simulium nigrimanum* triggers an antibody response to EC-5 (an antigenic domain of Desmoglein-1, responsible for the preclinical phase), and in susceptible individuals, subsequent responses to EC1-2 domains develop by epitope spreading, and thus full-blown ‘Wildfire’ of the skin.15

Are viruses or viral vaccines potential triggers for autoimmune bullous disease?

Sagi et al.16 have shown that in their cohort, patients with autoimmune bullous disease were found to have significantly higher prevalence of IgG antibodies demonstrating past infection with viruses such as HBV, HCV and CMV compared to controls but the authors did not suggest that this implied causality. There have also been reports of flu vaccines (including swine flu) triggering BP and again the mechanisms suggested have been skin inflammation and exposure of basement membrane proteins to the immune response.17,18

We have described a case of a patient who developed Covid19 maculo-papular and acral vesicular rashes initially, and this then evolved into BP during prolonged SARS-CoV2 infection. The estimated incidence rate of Covid19 infection in the over 70s in the United Kingdom in this period, was 0.3% or 3 per
The incidence rate of BP is less than 5 per 100,000. Therefore, the chances of a completely unrelated but concurrent manifestation of both diseases was less than 0.15 per 1 million (a x b).

It is therefore more plausible to assume that her skin disease was indeed associated with her viral infection, rather than random and purely coincidental. This rare association has not been reported so far in the pandemic, and it will be useful to test BP patients for SARS-Cov2 infection during this pandemic to determine whether this is a true but rare association.

CONFLICT OF INTERESTS
No conflict of interests have been declared.

AUTHOR CONTRIBUTIONS
P.K.C. Goon: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Writing – original draft; Writing – review & editing. O. Bello: Investigation;
Methodology; Writing – review & editing. L.A. Adamczyk: Formal analysis; Investigation; Methodology; Validation; Writing – review & editing. J.Y.H. Chan: Formal analysis; Investigation; Methodology; Validation; Writing – review & editing. H. Sudhoff: Conceptualization; Data curation; Investigation; Methodology; Project administration; Supervision; Validation; Visualization; Writing – review & editing. C.C. Banfield: Conceptualization; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Writing – review & editing.

ORCID
P.K.C. Goon © https://orcid.org/0000-0002-9940-7788

REFERENCES
1. Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med. 2018; 5:220.
2. Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Invest Dermatol. 2016;136:2495–2498.
3. Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132:1998–2004.
4. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.
5. Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78:1090–6.
6. Varpuluoma O, Forsti AK, Jokelainen J, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide Registry study. J Invest Dermatol. 2018;138:1659–61.
7. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131:637–43.
8. Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57:664–9.
9. Brown A, Bernier G, Mathieu M, et al. The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. Nat Genet. 1995;10:301–6.
10. Seppanen A, Autio-Harjainen H, Alafuzoff I, et al. Collagen XVII is expressed in human CNS neurons. Matrix Biol. 2006; 25:185–8.
11. Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016;136:2201–10.
12. Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71–7.
13. Gianotti R, Recalcati S, Fantini F, et al. Histopathological study of a broad spectrum of skin dermatoses in patients affected or highly suspected of infection by COVID-19 in the northern part of Italy: analysis of the many faces of the viral-induced skin diseases in previous and new reported cases. Am J Dermatopathol. 2020;42(8):564–570.
14. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e212–3.
15. Rodrigues DB, Pereira SA, dos Reis MA, et al. In situ detection of inflammatory cytokines and apoptosis in pemphigus foliaceus patients. Arch Pathol Lab Med. 2009;133:97–100.
16. Sagi L, Baum S, Agnon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev. 2011;10:327–35.
17. Downs AM, Lear JT, Bower CP, et al. Does influenza vaccination induce bullous pemphigoid? A report of four cases. Br J Dermatol. 1998;138:363.
18. Walmsey N, Hampton P. Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid. J Dermatol Case Rep. 2011;5:74–6.

How to cite this article: Goon PKC, Bello O, Adamczyk LA, Chan JYH, Sudhoff H, Banfield CC. Covid-19 dermatoses: Acral vesicular pattern evolving into bullous pemphigoid. Skin Health Dis. 2021;1:e6. https://doi.org/10.1002/ski2.6